RxSight, Inc. (RXST) 股票分析

公司概述

RxSight, Inc. operates as a commercial-stage medical technology company dedicated to the research, development, manufacturing, and sale of light adjustable intraocular lenses (LAL) specifically designed for use in cataract surgery within the United States. The enterprise functions within the Healthcare sector and the specialized Medical Devices industry, positioning itself at the intersection of advanced optics and surgical instrumentation. With a total market capitalization of $300.42M and an annual revenue (TTM) of $134.48M, the company maintains a workforce of 461 employees. These financial metrics indicate that while the firm has achieved a commercial stage with significant revenue generation, its valuation relative to book value and earnings suggests it is navigating a period of financial restructuring or heavy investment in product expansion.

财务健康

The company reported a trailing twelve-month revenue of $134.48M, yet posted a net income of -$38,944,000 and an EBITDA of -$44,925,000. The substantial gap between positive revenue and significant negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs or sales and marketing expenditures typical of a commercial-stage medical device firm. Free cash flow stands at -$1,625,250, which indicates that the company is currently burning cash, a situation that constrains immediate financial flexibility but may be consistent with growth-stage capital allocation strategies. Margin analysis shows a Gross Margin of 76.6%, reflecting efficient production and pricing power for the LAL products, while the Operating Margin of -34.8% and Profit Margin of -29.0% highlight the pressure of overhead costs before and after interest and taxes. Regarding liquidity and leverage, the company holds $228.13M in cash against $11.04M in debt, supported by a Debt to Equity ratio of 4.00 and a robust Current Ratio of 10.95. Despite the high leverage indicated by the debt-to-equity figure, the massive cash reserve and current ratio suggest a conservative balance sheet with ample short-term liquidity to cover obligations. Return on Equity is -14.0% and Return on Assets is -9.6%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate losses rather than returns, a common feature for firms in aggressive expansion phases.

估值评估

Valuation multiples present a complex picture, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -15.09. The disparity between an unavailable trailing P/E and a negative forward P/E implies that the market is pricing in a future path to profitability or continued earnings contraction rather than current earnings power. The Price to Book ratio is 1.09, indicating that the market values the company at slightly more than its book value, suggesting a neutral to slight premium over the tangible net assets. Alternative valuation metrics, including a Price to Sales ratio of 2.23 and an EV/EBITDA of -1.85, suggest the market is valuing the firm primarily on revenue generation rather than current earnings quality. The stock has traded between a 52-week high of $17.52 and a 52-week low of $5.90; without a specific current price provided, the valuation range establishes the volatility envelope within which the asset has moved over the last year. The Beta of 1.21 indicates that the stock price is 21% more volatile than the broader market, reflecting higher sensitivity to market fluctuations and sector-specific risks.

Growth & Income

Revenue growth (YoY) has declined by -18.9%, while Earnings Growth (YoY) is N/A due to the absence of reported earnings. The contraction in revenue suggests a potential headwind in market demand or a strategic shift in product mix, whereas the lack of earnings growth data precludes a direct comparison of profit expansion versus top-line performance. As the company does not pay a dividend, indicated by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it reinvests all available earnings, however small, back into the business rather than distributing income to shareholders. This non-dividend profile aligns with the company's status as a commercial-stage entity focused on sustaining operations and funding development rather than returning capital. Overall, the growth and income profile is defined by revenue contraction and a reliance on internal cash reserves rather than external financing or dividend support.